[Response to aflibercept in patients with fibrovascular pigment epithelial detachment refractory to ranibizumab in exudative age-related macular degeneration].
Service d'ophtalmologie, groupement des hôpitaux catholiques de Lille, université catholique de Lille, boulevard de Belfort, BP 387, 59020 Lille cedex, France. Electronic address: tran.hachau@ghicl.net.
T H C
TH
Tran
Clinique de la Louvière, 59042 Lille, France.
S
S
Dumas
Centre ophtalmologique de l'Odéon, 75006 Paris, France; Centre hospitalier intercommunal de Créteil, université Paris-Est-Créteil, Créteil, France.
F
F
Coscas
D000068258:Bevacizumab; D006801:Humans; D008268:Macular Degeneration; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins
D011993:Recombinant Fusion Proteins; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab